Please see what you are clicking on foxbusiness.com.
Astrazeneca as part of its ongoing investment of $3.5 billion American innovationopened the first US Manipulated Cell Therapy Manufacturing Facility in Maryland to help treat cancer patients.
The UK-based pharmaceutical giant said the new $300 million facility in Rockville represents confidence in America’s role as a “global leader in science, manufacturing and economic growth.”
“We understand the importance of what we do as our lives and health are at stake,” said Pam Cheng, executive vice president of global operations at Astrazeneca, at the facility’s official opening Monday. “I chose to do this in Maryland because I believe in that incredible talent, scientific leadership and a spirit of collaboration.”
Astrazeneca opened its first US Manipulated Cell Therapy Manufacturing Facility in Rockville, Maryland. (Fox News Digital/Fox News)
When in operation, the site supports treatment using a relatively new cancer treatment called CAR-T cell therapy Blood cancer Like lymphoma and leukemia.
Andrew Gordon, a cancer survivor diagnosed with multiple myeloma in 2013, said he used CAR-T cell therapy to combat the disease after the recurrence.
The multinational pharmaceutical company said the new Maryland facility represents confidence in America’s role as a “global leader in science, manufacturing and economic growth.” (Fox News Digital/Fox News)
“This is truly the cutting edge of cancer research,” Gordon said. “As patients, we are very grateful to AstraZeneca for the work they are trying to do here.”
Alternative cancer treatments could replace chemotherapy and surgery, studies suggest
The opening of the new facility comes from AstraZeneca CEO Pascal Soriot in comments made in recent weeks about investment in the US. He said the US may be more attractive for healthcare spending to invest in healthcare compared to other regions like Europe. To Reuters.
The Maryland site uses CAR-T cell therapy, a relatively new cancer treatment, to help treat hematologic cancers such as lymphoma and leukemia. (Fox News Digital/Fox News)
“Europe spends a significantly lower share of GDP on innovative medicines than the US, resulting in lagging behind the attractance. [research and development] Soriot said in a statement.
Financial markets are screaming about Trump’s tariffs
president Donald Trump We are looking for greater American innovation. It has recently touted a surge in US investments from companies such as Toyota, Amazon, and Johnson & Johnson. Trump’s White House won the first 100 days of its second term, acknowledged AstraZeneca’s increased investment in American manufacturing.
The pharmaceutical company’s US business currently generates around 43% of its global revenue. (Fox News Digital/Fox News)
The pharmaceutical company’s $3.5 billion investment in US research and manufacturing was first announced in November. It also includes the R&D center MassachusettsA specialist manufacturing facility in Texas, a next-generation manufacturing facility for Maryland’s biology, according to drug makers.
Click here to get your Fox business on the go
Astrazeneca’s US business currently generates around 43% of global revenue, but the company hopes the US will represent half of its global revenue by 2030.
“With 4,200 employees and over 9 billion doses produced annually across the US manufacturing network, we believe a future of advanced medicine should be built and guided at home,” AstraZeneca wrote in a statement.
